Trials / Completed
CompletedNCT01655680
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Nonsmokers
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 432 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 20 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a safety and efficacy study evaluating a experimental treatment for cognitive deficits in adults with schizophrenia.
Detailed description
This is a Phase 2 study designed to evaluate the safety and efficacy of ABT-126 in treating cognitive deficits in subjects with a diagnosis of schizophrenia. Eligible subjects will take study drug as an add-on treatment to their ongoing antipsychotic treatment regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABT-126 | ABT-126 Middle Dose |
| DRUG | ABT-126 | ABT-126 Low Dose |
| DRUG | ABT-126 | ABT-126 High Dose |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2012-05-01
- Primary completion
- 2014-04-01
- Completion
- 2014-07-01
- First posted
- 2012-08-02
- Last updated
- 2021-07-07
Locations
61 sites across 3 countries: United States, Russia, United Kingdom
Source: ClinicalTrials.gov record NCT01655680. Inclusion in this directory is not an endorsement.